Obesity Med Coverage In Medicare And Medicaid: A Late Gift By Biden To Pharma

 
• By Nielsen Hobbs

Proposed rule on GLP-1s sets up an expensive benefit that would need to be implemented (or rejected) by the incoming Trump administration. Move suggests the next round of drugs subject to Medicare price-setting will include Novo’s semaglutide – and could be announced by the Biden team before they leave.

The Trump administration could be stuck with the expensive decision by Biden’s HHS to expand Medicare coverage of anti-obesity medications. (Shutterstock)

More from Medicare

More from Geography